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Introduction
My long-term career goal is to be a leader in basic and translational breast cancer research, and have an impact on the prevention of breast cancer. To achieve the goal of this journey, a valuable postdoctoral training in breast cancer research in a setting with experienced, well established investigators is very important. The BC103928 Postdoc Fellowship Award granted me the opportunity to deepen my understanding of the mechanisms and underlying role of estrogens in the process of carcinogenesis leading to breast cancer. The goal of this study is to investigate the modulation of estrogen-depurinating DNA adducts by sulforaphane for breast cancer chemoprevention. I am under the supervision of a Mandatory Career Development Committee composed of Dr. Thomas Kensler (mentor), Dr. Nancy Davidson (co-mentor), Dr. Bruce Freeman and Dr. Kala Visvanathan. With this training, I will gain further experience in cell culture, animal models, clinical samples, mass spectrometry and estrogen metabolism at University of Pittsburgh. In addition to learning laboratory techniques, I will attend local, national and international meetings and workshops, classes and seminars that relate to mass spectrometry and clinical trial methods and practice. I have the opportunity to receive guidance from both my meetings with the Career Development Committee and from communications with other senior experts in breast cancer research in the Department of Pharmacology such as Dr. Steffi Oesterreich and Dr. Adrian Lee. In summary, this is a comprehensive and personalized training program to ensure the highest productivity and to effectively facilitate my career goal of transitioning into an independent breast cancer researcher. Body In the past year, I have been working on research and training tasks according to the original schedule. I have established a solid phase extraction method to partially purify estrogen metabolites and depurinating DNA adducts from cell culture medium. I have developed a UHPLC-MS/MS method to separate and quantify estrogen metabolites and depurinating DNA adducts and used this method to quantify levels in MCF-10A cell culture media treated with vehicle or sulforaphane and E 2 or 4-OHE 2 . Sulforaphane (SFN) is a potent inducer of detoxification enzymes such as NAD(P)H:quinone oxidoreductase (NQO1) and glutathione-S-transferase (GST) via the Kelch-like ECH-associated protein 1 (Keap1) -Nuclear Factor-E2-related factor (Nrf2) signaling pathway. NQO1 reduces the carcinogenic estrogen metabolite, Catechol Estrogen-3,4-Quinone (CE-3,4-Q), to catechols while GSTs detoxify it through nucleophilic addition. CE-3,4-Q can bind with DNA to form depurinating DNA adducts, leading to DNA damage via an estrogen receptor (ER) independent pathway. Thus, SFN may be an ideal chemoprevention agent to block estrogen-mediated carcinogenesis. To test the above hypothesis, I have treated MCF10A cells with either vehicle or SFN (10 μM) and E 2 (10µM) or 4-OHE 2 (10µM). The results show that NQO1 was up-regulated at the mRNA (~2fold), protein (~3fold) and activity levels (~3fold) by SFN treatment. Estrogen metabolites and depurinating DNA adducts in the cell culture medium were partially purified by solid phase extraction and then analyzed by UHPLC-ESI-MS/MS. Following E 2 treatment, the depurinated adducts 4-OHE 1/2 -1-N3Ade and 4-OHE 1/2 -1-N7Gua were significantly lower in SFN treated cells compared to vehicle (0.03±0.01 versus 0.07±0.02 pmole/10 6 cell, p=0.0294); 4-OHE 1/2 -glutathione conjugates were significantly higher following SFN treatment (1.54±0.37 versus 0. Note: Even though the title of the above posters might be the same or similar, the contents of above posters are different because the sample size increased with time and all the data were presented with updated data. This is your course confirmation! We would like to thank you for enrolling in the following course ( Please note by the submission of your on-line Pre-Registration you agree to adhere to our cancellation, Weather Related and refund policy that is list below: Cancellation Policy ·We reserve the right to cancel any course, 30 calendar days prior to the scheduled start date, due to insufficient enrollment.·We reserve the right to change the venue of the course, 30 calendar days prior to the scheduled start date.Travel arrangements should not be made more than 30 calendar days in advance, as the venue is subject to change. ·In the event of a venue change, you will be notified by a Thermo representative. Thermo will not be responsible for expenses incurred (for example, non-refundable airline reservations) if the course is cancelled or moved.·Cost for courses is quoted in U.S. dollars.·Payment in full is due upon course commencement.·Attendee substitutions may be made at any time (call us first to determine if course is appropriate).·Enrollment in your desired training course(s) is not guaranteed until receipt of this form, the pre-course questionnaire (if applicable), and confirmed method of payment. Weather Related Cancellation ·We reserve the right to cancel any course, by 2pm Eastern time the Friday prior to the course start date.·Thermo will not be responsible for expense incurred (for example, no-refundable airline reservations).·If a customer arrives to the area in advance and the course is cancelled by 2pm Eastern the Friday prior to the course start date; Thermo is not responsible for expenses incurred.·For weather advisories, please contact us at 800-532-4752 and speak directly with the registrar. Refund Policy ·100% refund for cancellations received 15+ business days prior to course date.·50% refund for cancellations received 10-15 business days prior to course date.·No refund for cancellations received fewer than 10 business days prior to course date.·No refund for no-shows. If you have any questions or need further information please feel free to contact us. We very much look forward to your attendance and participation in this retreat. We especially encourage you to bring students and fellows, as our trainees are so current and future research endeavors! We will need to limit the number of attendees at the Retreat, and therefore encourage you to register soon. Should we rea Retreat committee will make decisions based on active participation in WCRC activities.
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Libertas Academica la-press.com (+64-9) 476-3930 Dear Li:
A manuscript entitled "Catechol-<i>O</i>-methyltransferase-mediated metabolism of 4-hydroxyestradiol inhibits the growth of human renal cancer cells through the apoptotic pathway," with Dr Yuichiro Tanaka as corresponding author, has been submitted to Carcinogenesis, and we are writing to ask whether you could assess it for us. The abstract is shown below. We appreciate that there are many demands on your time, but would greatly value your evaluation of this article.
Could you please let us know whether you would be willing to review this paper for Carcinogenesis, bearing in mind that we would hope to receive the assessment within 2-3 weeks? If you are unable to review this manuscript, we would be grateful for any suggestions for suitable alternative referees, including senior members of your laboratory.
To record your reply automatically, click on the appropriate link below. Details of how to view the manuscript and submit your review will be e-mailed to you as soon as you have agreed. Long-term exposure to estrogen and its metabolites may play an important role in renal cell carcinogenesis. Catechol-<i>O</i>-methyltransferase (COMT) participates in the estrogen metabolism pathway by neutralizing toxic substances. Although reduced COMT activity has been suggested to be a risk factor for estrogen-associated cancers, no studies have investigated the biological significance of COMT in the pathogenesis of human renal cell cancers (RCC). We initially found that COMT levels are significantly decreased in human RCC tissues and cells suggesting it plays a suppressive role in tumor development. However, transient over-expression of COMT has no functional effect on RCC cell lines. In contrast, when cells over-expressing COMT are treated with its substrate 4-hydroxyestradiol (4-OHE<sub>2</sub>), growth is inhibited by apoptotic cell death. We also found that COMT over-expression combined with 4-OHE<sub>2</sub> induces up-regulation of growth arrest-and DNA damage-inducible protein α (GADD45α). We further show that down-regulation of GADD45α by a siRNA-mediated approach inhibits cell death, indicating the essential role of GADD45α in the underlying mechanism of COMT action in response to 4-OHE<sub>2</sub>. Finally, 4-methoxyestradiol (4-ME) fully reproduces the anti-proliferative function of COMT with 4-OHE<sub>2</sub> prevents RCC cell proliferation by enhancing apoptosis, and that GADD45α plays a critical role in the COMT-mediated inhibition of RCC.
"Intel ISEF Grand Awards Judge Chair" <judging@societyforscience. Once registered, you should check-in at your category room, pick-up a category ribbon and then spend the time prior to 5:30 p.m. reviewing the projects within your category on the exhibit hall floor. The exhibit hall opens at noon with no finalists present. At 5:30 p.m. all judges will be asked to go back to their respective category rooms for a buffet dinner and brief orientation by the category co-chairs. There will then be a Welcome and training session for all judges from 6:30 -8:00 p.m. in Hall A. Following this session, the co-chairs will meet their judges in the exhibit hall within their category area to distribute the specific judging interview schedules for the next morning.
On Wednesday, the Exhibit Hall will be open to judges at 7:00 a.m. and all judges are asked to report to their category rooms by 8:30 for final attendance verification and to receive their score cards. Judging and post-interview category deliberations will occupy all of Wednesday. The detailed schedule for your judging as well as the Judging Guide that explains the complete process is available on the SSP site at http://www.societyforscience.org/page.aspx?pid=290 PARKING: Parking has been arranged for judges and volunteers on Tuesday and Wednesday at the Grand Street Parking Lot between 11th and 12th Streets and Penn and Liberty. A map is available at the website address above. Those that park will need to ask their category co-chair for a chaser card to provide when exiting the garage each day.
MEALS:
All meals will be provided from dinner Tuesday, breakfast-lunch-dinner Wednesday. These will be in the judge`s meeting area.
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Send all inquiries to: Judging@societyforscience.org Thank you again for your commitment to science education and young scientists. We look forward to working with you.
Sincerely, Chuck University of Pittsburgh at Greensbur g UPMC UFE CHANGING ME!:!ICINE
